Last reviewed 2026-04-20 · How we verify

prostacyclin

Prostacyclin, marketed by United Therapeutics, is currently positioned in the allergic rhinitis market. The drug's key strength lies in its unique mechanism of action, which differentiates it from other treatments. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Allergic rhinitis
• Common cold
• Cough
• Nasal congestion
• Nasal discharge
• Pulmonary arterial hypertension
• Pulmonary hypertension
• Rhinitis

Common side effects

No common side effects on file.

Key clinical trials

• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (PHASE3)
• Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
• Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension
• Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD (PHASE2)
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension (PHASE3)
• Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO) (PHASE4)
• Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
• A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.